Creation of a long-acting nanoformulated dolutegravir

Brady Sillman; Aditya N. Bade; Prasanta K. Dash; Biju Bhargavan; Ted Kocher; Saumi Mathews; Hang Su; Georgette D. Kanmogne; Larisa Y. Poluektova; Santhi Gorantla; Joellyn McMillan; Nagsen Gautam; Yazen Alnouti; Benson Edagwa; Howard E. Gendelman

doi:10.1038/s41467-018-02885-x

Creation of a long-acting nanoformulated dolutegravir

Brady Sillman, Aditya N. Bade, Prasanta K. Dash, Biju Bhargavan, Ted Kocher, Saumi Mathews, Hang Su, Georgette D. Kanmogne, Larisa Y. Poluektova, Santhi Gorantla, Joellyn McMillan, Nagsen Gautam, Yazen Alnouti, Benson Edagwa, Howard E. Gendelman

Research output: Contribution to journal › Article

38 Scopus citations

Abstract

Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes. A hydrophobic and lipophilic modified DTG prodrug is encapsulated into poloxamer nanoformulations (NMDTG) and characterized by size, shape, polydispersity, and stability. Retained intracytoplasmic NMDTG particles release drug from macrophages and attenuate viral replication and spread of virus to CD4+ T cells. Pharmacokinetic tests in Balb/cJ mice show blood DTG levels at, or above, its inhibitory concentration of 64 ng/mL for 56 days, and tissue DTG levels for 28 days. NMDTG protects humanized mice from parenteral challenge of the HIV-1 strain for two weeks. These results are a first step towards producing a long-acting DTG for human use by affecting drug apparent half-life, cell and tissue drug penetration, and antiretroviral potency.

Original language	English (US)
Article number	443
Journal	Nature communications
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41467-018-02885-x
State	Published - Dec 1 2018

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
Physics and Astronomy(all)

Access to Document

10.1038/s41467-018-02885-x

Fingerprint Dive into the research topics of 'Creation of a long-acting nanoformulated dolutegravir'. Together they form a unique fingerprint.

Cite this

Sillman, B., Bade, A. N., Dash, P. K., Bhargavan, B., Kocher, T., Mathews, S., Su, H., Kanmogne, G. D., Poluektova, L. Y., Gorantla, S., McMillan, J., Gautam, N., Alnouti, Y., Edagwa, B., & Gendelman, H. E. (2018). Creation of a long-acting nanoformulated dolutegravir. Nature communications, 9(1), [443]. https://doi.org/10.1038/s41467-018-02885-x

Creation of a long-acting nanoformulated dolutegravir. / Sillman, Brady; Bade, Aditya N.; Dash, Prasanta K.; Bhargavan, Biju; Kocher, Ted; Mathews, Saumi; Su, Hang; Kanmogne, Georgette D.; Poluektova, Larisa Y.; Gorantla, Santhi ; McMillan, Joellyn; Gautam, Nagsen; Alnouti, Yazen ; Edagwa, Benson ; Gendelman, Howard E.

In: Nature communications, Vol. 9, No. 1, 443, 01.12.2018.

Research output: Contribution to journal › Article

Sillman, Brady ; Bade, Aditya N. ; Dash, Prasanta K. ; Bhargavan, Biju ; Kocher, Ted ; Mathews, Saumi ; Su, Hang ; Kanmogne, Georgette D. ; Poluektova, Larisa Y. ; Gorantla, Santhi ; McMillan, Joellyn ; Gautam, Nagsen ; Alnouti, Yazen ; Edagwa, Benson ; Gendelman, Howard E. / Creation of a long-acting nanoformulated dolutegravir. In: Nature communications. 2018 ; Vol. 9, No. 1.

@article{8eae0681a4674b6c9aecb70da60d48f2,

title = "Creation of a long-acting nanoformulated dolutegravir",

abstract = "Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes. A hydrophobic and lipophilic modified DTG prodrug is encapsulated into poloxamer nanoformulations (NMDTG) and characterized by size, shape, polydispersity, and stability. Retained intracytoplasmic NMDTG particles release drug from macrophages and attenuate viral replication and spread of virus to CD4+ T cells. Pharmacokinetic tests in Balb/cJ mice show blood DTG levels at, or above, its inhibitory concentration of 64 ng/mL for 56 days, and tissue DTG levels for 28 days. NMDTG protects humanized mice from parenteral challenge of the HIV-1 strain for two weeks. These results are a first step towards producing a long-acting DTG for human use by affecting drug apparent half-life, cell and tissue drug penetration, and antiretroviral potency.",

author = "Brady Sillman and Bade, {Aditya N.} and Dash, {Prasanta K.} and Biju Bhargavan and Ted Kocher and Saumi Mathews and Hang Su and Kanmogne, {Georgette D.} and Poluektova, {Larisa Y.} and Santhi Gorantla and Joellyn McMillan and Nagsen Gautam and Yazen Alnouti and Benson Edagwa and Gendelman, {Howard E.}",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41467-018-02885-x",

language = "English (US)",

volume = "9",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Creation of a long-acting nanoformulated dolutegravir

AU - Sillman, Brady

AU - Bade, Aditya N.

AU - Dash, Prasanta K.

AU - Bhargavan, Biju

AU - Kocher, Ted

AU - Mathews, Saumi

AU - Su, Hang

AU - Kanmogne, Georgette D.

AU - Poluektova, Larisa Y.

AU - Gorantla, Santhi

AU - McMillan, Joellyn

AU - Gautam, Nagsen

AU - Alnouti, Yazen

AU - Edagwa, Benson

AU - Gendelman, Howard E.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes. A hydrophobic and lipophilic modified DTG prodrug is encapsulated into poloxamer nanoformulations (NMDTG) and characterized by size, shape, polydispersity, and stability. Retained intracytoplasmic NMDTG particles release drug from macrophages and attenuate viral replication and spread of virus to CD4+ T cells. Pharmacokinetic tests in Balb/cJ mice show blood DTG levels at, or above, its inhibitory concentration of 64 ng/mL for 56 days, and tissue DTG levels for 28 days. NMDTG protects humanized mice from parenteral challenge of the HIV-1 strain for two weeks. These results are a first step towards producing a long-acting DTG for human use by affecting drug apparent half-life, cell and tissue drug penetration, and antiretroviral potency.

AB - Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes. A hydrophobic and lipophilic modified DTG prodrug is encapsulated into poloxamer nanoformulations (NMDTG) and characterized by size, shape, polydispersity, and stability. Retained intracytoplasmic NMDTG particles release drug from macrophages and attenuate viral replication and spread of virus to CD4+ T cells. Pharmacokinetic tests in Balb/cJ mice show blood DTG levels at, or above, its inhibitory concentration of 64 ng/mL for 56 days, and tissue DTG levels for 28 days. NMDTG protects humanized mice from parenteral challenge of the HIV-1 strain for two weeks. These results are a first step towards producing a long-acting DTG for human use by affecting drug apparent half-life, cell and tissue drug penetration, and antiretroviral potency.

UR - http://www.scopus.com/inward/record.url?scp=85041667492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041667492&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-02885-x

DO - 10.1038/s41467-018-02885-x

M3 - Article

C2 - 29402886

AN - SCOPUS:85041667492

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 443

ER -